DNMT3A突变对NPM1突变急性髓系白血病预后的影响
该研究分析了164例NPM1突变急性髓系白血病患者,发现DNMT3A突变不影响总体预后,FLT3-ITD预后分层独立于DNMT3A状态。DNMT3A突变与诱导后及巩固治疗后NPM1突变转录本更高、MRD持续阳性相关,并呈分子复发风险升高趋势。
要点
- DNMT3A突变在NPM1突变AML中不影响总体生存。
- FLT3-ITD预后分层独立于DNMT3A突变状态。
- DNMT3A突变与MRD清除延迟及分子复发风险升高趋势相关。
核心结论
- DNMT3A突变未改变FLT3-ITD对NPM1突变AML的总体预后影响,尽管MRD清除延迟,可能因MRD驱动的抢先干预。
研究设计与样本
- 纳入2项连续CETLAM方案中诊断的164例NPM1突变AML患者,且DNMT3A和FLT3状态可查。
主要发现
- DNMT3A突变状态对总体生存无预后影响(P = .2)。
- FLT3-ITD预后分层(FLT3WT = FLT3low > FLT3high)独立于DNMT3A突变状态。
- 94例可评估MRD,DNMT3A突变与诱导后(P = .012)和首次巩固后(P < .001)更高NPM1突变转录本数相关。
- 所有DNMT3A突变患者在首次巩固后均为MRD阳性(P < .001),且在第二和第三次巩固后MRD持续阳性(P = .027和P = .001)。
- DNMT3A突变患者分子复发风险呈升高趋势(P = .054)。
临床怎么用
- 在NPM1突变AML中,DNMT3A突变可提示MRD清除延迟,需关注MRD监测。
- FLT3-ITD预后分层应独立于DNMT3A突变状态进行。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The negative prognostic impact of internal tandem duplication of FLT3 (FLT3-ITD) in patients with acute myeloid leukemia with mutated NPM1 (AML-NPM1) is restricted to those with a higher FLT3-ITD allelic ratio (FLT3high; ≥0.5) and considered negligible in those with a wild-type (FLT3WT)/low ITD ratio (FLT3low). Because the comutation of DNMT3A (DNMT3Amut) has been suggested to negatively influence prognosis in AML-NPM1, we analyzed the impact of DNMT3Amut in FLT3-ITD subsets (absent, low, and high ratios). A total of 164 patients diagnosed with AML-NPM1 included in 2 consecutive CETLAM protocols and with DNMT3A and FLT3 status available were studied. Overall, DNMT3Amut status did not have a prognostic impact, with comparable overall survival (P = .2). Prognostic stratification established by FLT3-ITD (FLT3WT = FLT3low > FLT3high) was independent of DNMT3Amut status. Measurable residual disease (MRD) based on NPM1 quantitative polymerase chain reaction was available for 94 patients. DNMT3Amut was associated with a higher number of mutated NPM1 transcripts after induction (P = .012) and first consolidation (C1; P < .001). All DNMT3Amut patients were MRD+ after C1 (P < .001) and exhibited significant MRD persistence after C2 and C3 (MRD+ vs MRD-; P = .027 and P = .001, respectively). Finally, DNMT3Amut patients exhibited a trend toward greater risk of molecular relapse (P = .054). In conclusion, DNMT3Amut did not modify the overall prognosis exerted by FLT3-ITD in AML-NPM1 despite delayed MRD clearance, possibly because of MRD-driven preemptive intervention.
引用
- Oñate G, Bataller A, Garrido A, et al. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Adv. 2022. PMID: 34516636. doi:10.1182/bloodadvances.2020004136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。